2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
22
Lung Neoplasms
9
Lymphoma, Large-Cell, Anaplastic
4
Carcinoma
4
Carcinoma, Squamous Cell
2
Carcinoma, Large Cell
2
Brain Neoplasms
2
Adenocarcinoma
2
ALK-positive Advanced NSCLC
2
Sexual Dysfunction, Physiological
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Meningioma
1
Granuloma, Plasma Cell
1
Gastrointestinal Neoplasms
1
Eunuchism
1
Erectile Dysfunction
1
Ependymoma
1
Disease Progression
1
Carcinoma, Pancreatic Ductal
1
Breast Neoplasms
1
ALK-positive NSCLC
1
ALK+ Advanced NSCLC
1
Interventions
Magnetic Resonance Spectroscopy
16
Hydroxyurea
7
Everolimus
7
Bevacizumab
7
lutetium Lu 177 dotatate
6
gallium Ga 68 dotatate
6
Radiosurgery
6
Proton Therapy
6
Specimen Handling
5
pembrolizumab
4
Surveys and Questionnaires
4
Surgical Procedures, Operative
4
Radiotherapy
4
Imatinib Mesylate
4
Cyclophosphamide
4
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
4
aldesleukin
3
abemaciclib
3
Tranexamic Acid
3
Temozolomide
3
Sunitinib
3
Sodium Chloride
3
Radiotherapy, Intensity-Modulated
3
Observation
3
Nivolumab
3
Ga(III)-DOTATOC
3
90Y-octreotide, DOTA-Tyr(3)-
3
vistusertib
2
trametinib
2
ribociclib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Meningioma
×
brigatinib
×
Clear all
NCT04374305
2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2
Recruiting
109 enrolled